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Abstract
Introduction Acetaminophen (paracetamol) is mainly
metabolized via glucuronidation and sulphation, while the
minor pathway through cytochrome P450 (CYP) 2E1 is
held responsible for hepatotoxicity. In obese patients,
CYP2E1 activity is reported to be induced, thereby
potentially worsening the safety profile of acetaminophen.
The aim of this study was to determine the pharmacoki-
netics of acetaminophen and its metabolites (glucuronide,
sulphate, cysteine and mercapturate) in morbidly obese and
non-obese patients.
Methods Twenty morbidly obese patients (with a median
total body weight [TBW] of 140.1 kg [range
106–193.1 kg] and body mass index [BMI] of 45.1 kg/m2
[40–55.2 kg/m2]) and eight non-obese patients (with a
TBW of 69.4 kg [53.4–91.7] and BMI of 21.8 kg/m2
[19.4–27.4]) received 2 g of intravenous acetaminophen.
Fifteen blood samples were collected per patient. Popula-
tion pharmacokinetic modelling was performed using
NONMEM.
Results In morbidly obese patients, the median area under
the plasma concentration–time curve from 0 to 8 h
(AUC0–8h) of acetaminophen was significantly smaller
(P = 0.009), while the AUC0–8h ratios of the glucuronide,
sulphate and cysteine metabolites to acetaminophen were
significantly higher (P = 0.043, 0.004 and 0.010, respec-
tively). In the model, acetaminophen CYP2E1-mediated
clearance (cysteine and mercapturate) increased with lean
body weight [LBW] (population mean [relative standard
error] 0.0185 L/min [15 %], P\ 0.01). Moreover, accel-
erated formation of the cysteine and mercapturate
metabolites was found with increasing LBW (P\ 0.001).
Glucuronidation clearance (0.219 L/min [5 %]) and sul-
phation clearance (0.0646 L/min [6 %]) also increased with
LBW (P\ 0.001).
Conclusion Obesity leads to lower acetaminophen con-
centrations and earlier and higher peak concentrations of
acetaminophen cysteine and mercapturate. While a higher
dose may be anticipated to achieve adequate acet-
aminophen concentrations, the increased CYP2E1-medi-
ated pathway may preclude this dose adjustment.
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Key Points
Cytochrome P450 (CYP) 2E1–mediated clearance of
acetaminophen to acetaminophen cysteine and
mercapturate increases with lean body weight, while
the formation of these cysteine and mercapturate
metabolites is also accelerated.
Besides increased CYP2E1-mediated clearance,
glucuronidation and sulphation clearance are also
increased in morbidly obese patients, which results
in lower exposure to acetaminophen.
While a higher dose of acetaminophen may be
anticipated to achieve adequate acetaminophen
concentrations in morbidly obese patients, the
increased CYP2E1-mediated pathway may preclude
this dose adjustment.
1 Introduction
Worldwide, the prevalence rates of obesity (body mass
index [BMI] C30 kg/m2) are increasing. In the USA,
roughly a third of men (31.6 %) and women (33.9 %) were
obese in 2013 [1]. Also, in other parts of the world—i.e. the
Middle East (Qatar, Kuwait and Saudi Arabia), Africa
(Libya, South Africa and Egypt) and Oceania (Tonga,
Samoa and Kiribati)—high prevalence rates of obesity
(30–69.1 %) have been reported [1].
Acetaminophen (paracetamol) is a frequently used anal-
gesic in the peri- and postoperative setting. After bariatric
surgery or weight loss surgery, scheduled intravenous acet-
aminophen has been reported to significantly reduce narcotic
analgesic requirements during the first 24-h postoperative
period [2]. Acetaminophen is extensively metabolized by
different metabolic pathways in the liver. The main path-
ways are glucuronidation (around 55 %, by uridine diphos-
phate [UDP] glucuronosyltransferases [UGTs]) and
sulphation (around 30 %, by sulphotransferase) [3–5], while
only 2–5 % of acetaminophen is excreted unchanged [3, 5].
Approximately 5–10 % of acetaminophen is metabolized by
cytochrome P450 (CYP), primarily by the CYP2E1 enzyme
[6–8], to the toxic metabolite N-acetyl-p-benzoquinone
imine (NAPQI) [3–5, 9]. At therapeutic doses, NAPQI is
immediately inactivated by conjugationwith glutathione to a
neutral metabolite and is excreted as cysteine and mercap-
turate metabolites in urine [10]. Hepatotoxicity occurs when
glutathione stores are depleted (e.g. after an acetaminophen
overdose or chronic alcohol abuse), resulting in conjugation
ofNAPQI to cytosolic andmitochondrial proteins, leading to
hepatocellular necrosis [10, 11]. Intentional acetaminophen
overdose is the most common cause of acute liver failure in
the USA [12].
In obese subjects, both the volume of distribution and
the total clearance of acetaminophen are reported to be
increased in comparison with non-obese subjects [13]. As
such, obese patients may need higher loading and main-
tenance doses of acetaminophen. However, since one of the
metabolic pathways of acetaminophen (i.e. the CYP2E1-
mediated pathway) is involved in hepatotoxicity, it is
important to explore the separate contributions of the dif-
ferent metabolic pathways to the increased total clearance
of acetaminophen. To date, the contributions of the dif-
ferent metabolic pathways of acetaminophen have not been
investigated in morbidly obese patients. In obese patients,
glucuronidation capacity and CYP2E1-mediated clearance
or CYP2E1 expression are expected to be induced [14–19],
while the influence of obesity on sulphation is unclear [20–
23]. It is anticipated that non-alcoholic fatty liver disease
(NAFLD), which is associated with obesity, is the under-
lying cause of increased CYP2E1 expression in obese
patients [24]. The aim of this study was to determine the
pharmacokinetics of acetaminophen, with a specific
emphasis on the contributions of the metabolites (glu-
curonide, sulphate, cysteine and mercapturate), in morbidly
obese patients in comparison with non-obese patients.
2 Methods
2.1 Patients
Morbidly obese adult patients (BMI[40 kg/m2) undergoing
bariatric surgery (laparoscopic gastric bypass and sleeve
surgery) and non-obese adult patients undergoing oral and
maxillofacial surgery were considered for participation in
the study. Patients were excluded if they were pregnant or
breastfeeding, were smokers, suffered from renal insuffi-
ciency (glomerular filtration rate [GFR;Modification of Diet
in Renal Disease (MDRD)]\60 mL/min1.73 m2), or had a
liver disease identified by liver function tests (aspartate
aminotransferase [AST] or alanine aminotransferase [ALT]
[3 times the upper limit of normal values), type 2 diabetes
mellitus, Gilbert–Meulengracht syndrome or prior exposure
to acetaminophen within a 24-h period. In addition, patients
with chronic alcohol intake, patients who had used alcohol
within the previous 72 h and patients treated with drugs
known to affect CYP2E1 (disulfiram and isoniazide) or UGT
(such as oestradiol-containing contraceptives, certain
antiepileptics and antiretroviral drugs) were excluded.
Before participation, patients provided written informed
consent. The study was approved by the local human
research and ethics committee of St. Antonius Hospital
(VCMO, NL39958.100.12) and was conducted in
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accordancewith the principles of the Declaration of Helsinki
and the Medical Research Involving Human Subjects Act
(WMO) of the Netherlands.
2.2 Study Design
In this prospective observational study (ClinicalTrials.gov
study ID NCT01764555; EudraCT number 2012-000956-
32) 20 morbidly obese and 8 non-obese patients were
studied on the day of surgery. All patients received a 2 g
intravenous dose of acetaminophen (two flacons of Frese-
nius Kabi 10 mg/mL, 100 mL administered over 20 min
with a volumetric pump) before induction of anaesthesia.
Blood samples were collected at T = 0, 2.5, 7.5, 15, 30 and
45 min; and 1, 1.5, 2, 2.5, 3, 4, 5, 6 and 8 h after the end of
the 2 g infusion. After 8 h of blood sampling, the standard
postoperative pain protocol was initiated (i.e. 1 g of
intravenous acetaminophen every 6 h). One last blood
sample was taken at 24 h after the end of the 2 g acet-
aminophen infusion and other acetaminophen doses given
according to the standard protocol. Blood samples were
collected in lithium–heparin tubes and centrifuged at
2000g for 10 min at 4 C, and the plasma was stored at -
80 C until analysis.
Blood samples for liver function tests (AST, ALT,
prothrombin time [PT], c-glutamyltranspeptidase [c-GT]
and bilirubin) were collected before acetaminophen
administration and at T = 24 h. Blood samples for insulin
resistance (homeostatic model assessment of insulin resis-
tance [HOMA-IR], (fasting insulin levels and glucose
levels)), lipid levels (free fatty acid, triglyceride and
cholesterol levels) and C-reactive protein (CRP) levels
were collected before acetaminophen administration.
HOMA-IR was calculated as (glucose 9 insulin)/22.5.
2.3 Drug Assays
Acetaminophen, acetaminophen glucuronide, acetaminophen
sulphate, acetaminophen glutathione, acetaminophen cys-
teine and acetaminophen mercapturate were measured using
high-performance liquid chromatography–electrospray ion-
ization–tandem mass spectrometry (HPLC–ESI–MS/MS) at
the Center for Human Toxicology, University of Utah (Salt
Lake City, UT, USA) [25]. The assays were linear over
0.05–50 lg/mL for acetaminophen, acetaminophen glu-
curonide and acetaminophen sulphate, and over
0.025–5.0 lg/mL, 0.01–5.0 lg/mL and 0.01–1.0 lg/mL for
acetaminophen glutathione, acetaminophen cysteine and
acetaminophen mercapturate, respectively, with the lower
limits of the ranges representing the lower limits of quantifi-
cation (LLOQs) of acetaminophen and its metabolites. Intra-
and inter-assay accuracies ranged from80 to112 %, and intra-
and inter-assay imprecision did not exceed 15 %.
2.4 Statistical Analysis
The area under the plasma concentration–time curve
(AUC) from 0 to 8 h (AUC0–8h) values for acetaminophen,
acetaminophen glucuronide, acetaminophen sulphate,
acetaminophen cysteine and acetaminophen mercapturate
after dosing of acetaminophen were calculated for each
patient separately, using the linear trapezoidal rule in
R software (version 3.0.1) [26]. One non-obese patient was
excluded from AUC0–8h calculation, since this patient had
acetaminophen and metabolite concentrations measured
only until 6 h, instead of 8 h, post-dose. The AUC0–8h ratio
of each metabolite to acetaminophen (AUC0–8h metab/
AUC0–8h apap) was calculated for all metabolites in all
individuals. The Mann–Whitney test was applied to test
statistical differences in the median AUC0–8h values for
acetaminophen, the metabolite-to-acetaminophen ratios
and demographic variables between morbidly obese and
non-obese patients. The Wilcoxon rank test was used to test
statistical differences between liver function samples
before acetaminophen administration (T = 0) and 24 h
after administration (T = 24). These statistical analyses
were performed using IBM SPSS version 22 software.
2.5 Population Pharmacokinetic Analysis
and Internal Model Validation
Acetaminophen and metabolite data were analysed using
non-linear mixed effects modelling with NONMEM ver-
sion 7.2 software (Icon Development Solutions, Hanover,
MD, USA) [27]. Pirana version 2.9.1 [28], R version 3.0.1
[26], Xpose version 4.5.0 [28] and Psn version 3.6.2 [28]
software were used to evaluate and visualize the data.
Concentrations were expressed in micromoles per litre,
using the molecular weights of acetaminophen, acet-
aminophen glucuronide, acetaminophen sulphate, acet-
aminophen cysteine and acetaminophen mercapturate
(151.16, 327.29, 231.23, 270.30 and 312.24 g/mol, respec-
tively), and the concentrations were logarithmically trans-
formed. No glutathione concentrations could be measured
in either of the patient groups (\LLOQ). For acet-
aminophen, acetaminophen glucuronide, acetaminophen
sulphate, acetaminophen cysteine and acetaminophen mer-
capturate, 1 sample (0.25 %), 0 samples (0 %), 0 samples
(0 %), 2 samples (0.49 %) and 70 samples (17.3 %),
respectively, were below the LLOQs and were removed
from the analysis [29, 30]. The first-order conditional esti-
mation method was used for model development. Dis-
crimination between different models was guided by the
likelihood ratio test, by comparison of the objective func-
tion value (OFV) [i.e. -2 log likelihood (-2LL)] between
nested models. A P value of\0.05, representing a change
in the OFV [DOFV] of -3.84 for one degree of freedom,
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was considered statistically significant. In addition, good-
ness-of-fit plots for acetaminophen, acetaminophen glu-
curonide, acetaminophen sulphate, acetaminophen cysteine
and acetaminophen mercapturate in morbidly obese and
non-obese patients (observed versus individual-predicted
concentrations, observed versus population-predicted con-
centrations, conditional weighted residuals [CWRES] ver-
sus time after dose, and CWRES versus population-
predicted concentrations) were used for diagnostic pur-
poses. Furthermore, precision of parameter estimates, the
correlation matrix and visual improvement in the individual
plots were used to evaluate the model. Pharmacokinetic
models incorporating one, two or three compartments for
acetaminophen and one or two compartments for the
metabolites were tested. To capture eventual delay in for-
mation of acetaminophen metabolites, a varying number of
transit compartments was tested. The mean transit time
(MTT) was calculated from the transit compartment rate
constant (Ktr) with n/Ktr, where n is the number of transit
compartments. The CYP2E1 metabolites, i.e. acet-
aminophen cysteine and acetaminophen mercapturate, were
modelled in one compartment [31]. The volume of distri-
bution of acetaminophen sulphate (Vsulphate) was assumed to
be 5.66 L (5.66 FIX) [31], and the volume of distribution of
acetaminophen cysteine and mercapturate (Vcysteine and mer-
capturate) was assumed to be 15.6 L (15.6 FIX) [31] (Fig. 1).
The unchanged acetaminophen clearance (CLunchanged) was
assumed to be 5 % of the total clearance (CLtot; calculated
as CLtot = CLunchanged ? CLgluc ? CLsulph ? CLCYP2E1)
of a 70 kg individual (Fig. 1), where CLgluc is glu-
curonidation clearance, CLsulph is sulphation clearance and
CLCYP2E1 is CYP2E1-mediated clearance. Inter-individual
variability (IIV) was assumed to follow a log-normal dis-
tribution. Residual variability was tested using proportional,
additive or combined proportional and additive error mod-
els for acetaminophen and the metabolites. For internal
model evaluation, a bootstrap resampling method using
1000 replicates and visual predictive checks (VPCs) strati-
fied for acetaminophen, acetaminophen glucuronide, acet-
aminophen sulphate, and acetaminophen cysteine and
mercapturate, using 1000 simulated data sets of individuals
from the original data set, were used.
2.6 Covariate Model
The tested covariates were total body weight (TBW), BMI,
lean body weight (LBW; according to the equation of
Janmahasatian et al. [32]), age and sex. Covariates were
plotted independently against the eta (g) estimates of the
pharmacokinetic parameters to visualize potential relations.
Continuous covariates were tested using linear and power
equations (Eqs. 1, 2):
Pi ¼ Ppð1þ Y COV COVmedianð ÞÞ ð1Þ
Pi ¼ Pp COV=COVmedianð ÞX ð2Þ
where Pi and Pp represent the individual and population
parameter estimates, respectively, COV represents the
covariate, COVmedian represents the median value of the
covariate for the population, Y represents a correlation
factor between the population pharmacokinetic parameter
and the change in the covariate value for a linear function,
and X represents the exponent for a power function. The
categorical covariate sex was examined by calculation of a
separate parameter for each category of the covariate.
Potential covariates were entered into the model one at a
time and statistically tested by the likelihood ratio test. In
addition, if applicable, a reduction in IIV (omega [x]) of
Fig. 1 Schematic illustration of
the population pharmacokinetic
model. CLunchanged unchanged
clearance of acetaminophen,
CLgluc glucuronidation
clearance, CLsulp sulphation
clearance, CLCYP2E1 CYP2E1-
mediated clearance, CLE gluc
glucuronide elimination
clearance, CLE sulph sulphate
elimination clearance,
CLE cys&mercap cysteine &
mercapturate elimination
clearance, KtrCYP2E1 CYP2E1
transit compartment rate
constant, Ktrgluc glucuronide
transit compartment rate
constant, Q inter-compartmental
clearance of acetaminophen
sulphate between the central and
peripheral compartment,
V volume of distribution
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the parameter was evaluated upon inclusion of the
covariate on the parameter. Further, trends in the random
effects of the parameter versus the covariate involved were
observed. When more than one significant covariate was
identified, the covariate-adjusted model with the largest
decrease in the OFV was chosen as a basis to sequentially
explore the influence of additional covariates with the use
of the same criteria. Finally, after forward inclusion
(P\ 0.01), a backward exclusion procedure was applied to
justify the inclusion of a covariate (P\ 0.001). The choice
of the final covariate model was further evaluated as dis-
cussed in the ‘Population Pharmacokinetic Analysis and
Internal Model Validation’ section.
2.7 Simulations
To examine the effect of obesity on acetaminophen and
metabolite concentrations, the final population pharma-
cokinetic model was used to simulate concentration–time
curves upon a 2 g intravenous infusion (administration
time 20 min) in four typical patients from the data set, i.e. a
non-obese patient weighing 60.1 kg (LBW 41.2 kg) and
three morbidly obese patients weighing 106, 134 and
193 kg (LBWs 51.3, 65.8 and 96.2 kg, respectively). The
134 kg patient represents a patient around the median body
weight, and the 106 and 193 kg individuals represent the
two extremes in the data set of the morbidly obese patients
in the study population.
3 Results
3.1 Patients and Data
Twenty morbidly obese patients and eight non-obese
patients participated in this study. Median numbers of 15
acetaminophen samples, 15 acetaminophen glucuronide
samples, 15 acetaminophen sulphate samples, 15 acet-
aminophen cysteine samples and 12 acetaminophen mer-
capturate samples per patient were available for analysis.
The patient characteristics are summarized in Table 1.
Morbidly obese patients had significantly higher levels of
c-GT, triglycerides, glucose, insulin, HOMA-IR and CRP
than non-obese patients before administration of acet-
aminophen. According to the standard postoperative pain
protocol, morbidly obese and non-obese patients received
(in addition to the 2 g intravenous acetaminophen study
dose) median acetaminophen doses of 3 g (0–3 g) and 2 g
Table 1 Demographics of 20
morbidly obese patients and 8
non-obese patients
Variable Morbidly obese
patients, n = 20
Non-obese
patients, n = 8
P value
Female/male [n] 15/5 4/4 –
Age [years] 41.5 (22–58) 41.0 (18–50) [0.05
Body weight [kg] 140.1 (106–193.1) 69.6 (53.4–91.7) 0.001
LBW [kg] [32] 65.4 (50.5–96.2) 50.9 (36.0–67.5) 0.049
BMI [kg/m2] 45.1 (40–55.2) 21.8 (19.4–27.4) 0.001
Waist-to-hip ratio 0.85 (0.74–1.25) 0.79 (0.67–0.95) [0.05
Surgery duration [min] 59 (36–95) 110.5 (24–353) 0.029
AST [U/L] 26.0 (14.0–40.0) 22.0 (18.0–28.0) [0.05
ALT [U/L] 30.5 (12.0–58.0) 19.5 (7.0–33.0) [0.05
c-GT [U/L] 29.5 (13.0–99.0) 12.5 (8.0–27.0) 0.004
Bilirubin [lmol/L] 6.0 (3.0–17.0) 8.0 (4.0–18.0) [0.05
PT [s] 12.8 (12.3–13.9) 12.9 (12.4–13.4) [0.05
Albumin [g/L] 42.1 (38.9–48.4) 44.7 (40.5–48.7) [0.05
Creatinine [lmol/L] 62.5 (48.0–100.0) 75.5 (52.0–96.0) [0.05
Cholesterol [mmol/L] 4.9 (3.2–6.5) 5.2 (3.4–6.6) [0.05
Triglycerides [mmol/L] 1.3 (0.6–2.8) 0.8 (0.5–1.4) 0.013
FFA [mmol/L] 0.9 (0.6–1.7) 0.6 (0.2–1.2) [0.05
Glucose [mmol/L] 5.4 (4.6–7.5) 5.0 (4.6–5.5) 0.023
Insulin [mU/L] 23.0 (8.3–66.5) 8.9 (2.6–19.8) 0.001
HOMA-IR 5.7 (1.8–22.2) 2.0 (0.5–4.8) 0.001
CRP [mg/L] 6.5 (3.0–21.0) \1 (\1–5) 0.001
Values are expressed as median (range) unless specified otherwise
c-GT c-glutamyltranspeptidase, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body
mass index, CRP C-reactive protein, FFA free fatty acids, HOMA-IR homeostatic model assessment of
insulin resistance, LBW lean body weight, PT prothrombin time
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(range 0–4 g), respectively, over 24 h (P[ 0.05), whereby
three morbidly obese patients received acetaminophen as a
rectal dose and one morbidly obese patient received it as an
oral dose.
3.2 Observed Acetaminophen and Metabolite
Concentrations
The median AUC0–8h value of acetaminophen was statisti-
cally lower in morbidly obese patients (n = 20) than in non-
obese patients (n = 7) [37,795 versus 45,909 lmolmin/L,
P = 0.009]. The median AUC0–8h ratios of acetaminophen
glucuronide, acetaminophen sulphate and acetaminophen
cysteine to acetaminophen were significantly higher in
morbidly obese patients than in non-obese patients
(P = 0.043, 0.004 and 0.010, respectively) (Fig. 2a–c).
There was no difference in the median AUC0–8h ratio of
acetaminophen mercapturate to acetaminophen in morbidly
obese patients compared with non-obese patients (P[ 0.05)
(Fig. 2d). The time to reach the maximum plasma concen-
tration (tmax) of acetaminophen cysteine significantly
decreased with TBW (r = -0.52, P = 0.005).
3.3 Population Pharmacokinetic Model
and Internal Model Evaluation
A one-compartment model for acetaminophen, acet-
aminophen glucuronide and acetaminophen cysteine and
mercapturate, and a two-compartment model for acet-
aminophen sulphate, with equalized volumes of
distribution, best described the data (Fig. 1). The central
and peripheral volume of acetaminophen sulphate were
equalized, since these values were almost equal and the
model resulted in a similar OFV (P[ 0.05). A two-com-
partment model for acetaminophen glucuronide and acet-
aminophen cysteine and mercapturate improved the model
fit but could not be accurately estimated; therefore, a one-
compartment model for these metabolites was preferred to
a two-compartment model. For the glucuronide metabolite
and the cysteine and mercapturate metabolites, a transit
compartment model (n = 1 transit compartment) was
added (P\ 0.001) (Fig. 1) to capture the delay in
metabolite formation, which was observed in the CWRES-
versus-time plot of these metabolites. Inclusion of more
transit compartments did not improve the model fit for the
glucuronide metabolite and the cysteine and mercapturate
metabolites (P[ 0.05). Residual variability was best
described by four proportional error models, i.e. for the
acetaminophen, acetaminophen glucuronide, acet-
aminophen sulphate, and acetaminophen cysteine and
mercapturate concentrations. Table 2 shows the parameter
estimates of the base model without covariates.
The systematic covariate analysis identified a significant
influence of LBW or TBW on seven different parameters.
The first covariate was LBW for CYP2E1 transit com-
partment rate constant (KtrCYP2E1), which was found to
increase with LBW in a non-linear manner (P\ 0.001,
DOFV -38), implying a decrease in the mean transit time
(MTT) of acetaminophen cysteine and mercapturate in
obese individuals (MTT = 1/Ktr). Then LBW was
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Fig. 2 Area under the plasma
concentration–time curve from
0 to 8 h (AUC0–8h) metabolite-
to-acetaminophen ratios of
a acetaminophen glucuronide,
b acetaminophen sulphate,
c acetaminophen cysteine and
d acetaminophen mercapturate
in non-obese patients (n = 7)
versus morbidly obese patients
(n = 20) after a 2 g intravenous
acetaminophen dose. *P\ 0.05
(Mann–Whitney test)
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Table 2 Population pharmacokinetic parameters of the base and final pharmacokinetic models for acetaminophen in 20 morbidly obese patients
and 8 non-obese patients, and results from bootstrap analysis of the final model (996/1000 resamples successful)
Parameter Base model (RSE %) Final model (RSE %) Bootstrap
(95 % confidence interval)
Vacetaminophen [L] 64.4 (5.3) –
Vacetaminophen = V65.2 kg 9 [LBW/65.2]
S
V65.2 kg – 67.2 (2.8) 67.3 (64.1–70.9)
S – 0.90 (17.4) 0.90 (0.59–1.22)
CLgluc [L/min] 0.209 (7.5) –
CLgluc = CLgluc,65.2 kg 9 [LBW/65.2]
T
CLgluc,65.2 kg – 0.224 (5) 0.223 (0.202–0.246)
T – 1.33 (17) 1.34 (0.85–1.75)
CLsulph [L/min] 0.062 (7) –
CLsulph = CLsulph,65.2 kg 9 [LBW/65.2]
U
CLsulph,65.2 kg – 0.065 (6) 0.065 (0.057–0.073)
U – 0.92 (19.9) 0.92 (0.55–1.34)
CLCYP2E1 [L/min] 0.018 (14.8) –
CLCYP2E1 = CLCYP2E1,65.2 kg 9 [LBW/65.2]
W
CLCYP2E1,65.2 kg – 0.021 (14.6) 0.021 (0.015–0.026)
W – 0.67 (27.4) 0.71 (0.21–1.38)
Vglucuronide [L] 29.7 (5.6) –
Vglucuronide = V130.9 kg 9 [TBW/130.9]
X
V130.9 kg – 32.3 (4.1) 32.4 (29.7–34.9)
X – 0.55 (23.3) 0.56 (0.27–0.83)
Vsulphate,central = Vsulphate,peripheral [L] 5.66 FIX 5.66 FIX 5.66 FIX
Q [L/min] 0.346 (14.2) 0.339 (19.6) 0.338 (0.245–0.511)
Vcysteine and mercapturate [L] 15.6 FIX 15.6 FIX 15.6 FIX
KtrCYP2E1 [min
-1] 0.0063 (11.7)a –
KtrCYP2E1 = Ktr65.2 kg 9 [LBW/65.2]
Y
Ktr65.2 kg – 0.0057 (12.2)
b 0.0058 (0.0047–0.0079)
Y – 1.1 (33) 1.12 (0.19–1.79)
Ktrgluc [min
-1] 0.094 (11) 0.095 (11.5)c 0.095 (0.076–0.121)
CLE gluc [L/min] 0.211 (6.9) –
CLE gluc = CLE gluc,65.2 kg 9 [LBW/65.2]
Z
CLE gluc,65.2 kg – 0.222 (6.3) 0.221 (0.198–0.251)
Z – 0.89 (31) 0.90 (0.26–1.50)
CLE sulph [L/min] 0.097 (3.3) 0.096 (3.4) 0.096 (0.090–0.102)
CLE cys and mercap [L/min] 0.294 (13.2) 0.329 (14.5) 0.324 (0.226–0.423)
Inter-individual variability [%]
Vacetaminophen 26.4 (39.4) 14.4 (32.1) 13.9 (9.6–17.5)
CLgluc 36.6 (31.9) 21.8 (32.5) 21.0 (13.6–27.8)
CLsulph 33.6 (30) 24.3 (30.1) 23.0 (16.1–30.7)
CLCYP2E1 58.6 (46.1) 23.3 (37.4) 21.4 (12.0–29.8)
Vglucuronide 28.2 (30) 22.5 (29.5) 21.1 (13.1–27.5)
CLE gluc 35.4 (32) 30.3 (23.9) 28.3 (20.0–36.1)
CLE cys and mercap 52 (34.1) 34.9 (33.4) 34.0 (21.8–49.2)
Residual variability [%]
Proportional error for acetaminophen 17.2 (26.9) 17.1 (27) 16.7 (13.4–21.6)
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identified as the strongest predictor for the volume of dis-
tribution of acetaminophen (Vacetaminophen; P\ 0.001,
DOFV -32) and was selected over sex, which provided a
DOFV of only -16. In addition, CLgluc and CLsulph proved
to increase non-linearly with LBW (P\ 0.001, DOFV -
31; and P\ 0.001, DOFV -18, respectively). The volume
of distribution of acetaminophen glucuronide (Vglucuronide)
increased in a non-linear manner with TBW (P\ 0.001,
DOFV -12). The glucuronide elimination clearance
(CLE gluc) increased with LBW (P\ 0.001, DOFV -11).
Lastly, LBW was a significant parameter for CLCYP2E1
(P\ 0.01, DOFV -8). Although the statistical significance
for this last covariate was limited in the backward analysis
(P\ 0.05, DOFV ?4.4), LBW on CLCYP2E1 was kept in
the model, since an improved fit in the goodness-of-fit plots
of acetaminophen cysteine and mercapturate for the non-
obese patients was shown.
Figure 3 shows the empirical Bayes estimates (EBEs) of
the metabolic pathways of acetaminophen (i.e. CLgluc,
CLsulph and CLCYP2E1) versus LBW. After inclusion of the
covariates in the model, the trends in the g values of the
parameters and the covariate disappeared, and no residual
trends were observed (see Electronic Supplementary
Material Fig. S1). This was also reflected by the reduction
in IIV in the final model parameters in comparison with the
IIV of the base model (Table 2).
The final model parameters are summarized in Table 2.
Observed versus individual-predicted concentrations and
observed versus population-predicted concentrations of
acetaminophen, acetaminophen glucuronide, acet-
aminophen sulphate, and acetaminophen cysteine and
mercapturate are shown in Fig. 4. The bootstrap analysis
was successful in 99.6 % of the runs and confirmed the
model parameters (Table 2). Finally, VPCs for acet-
aminophen, acetaminophen glucuronide, acetaminophen
sulphate, and acetaminophen cysteine and mercapturate for
both morbidly obese and non-obese patients indicated good
predictive performance, with good agreement between the
Table 2 continued
Parameter Base model (RSE %) Final model (RSE %) Bootstrap
(95 % confidence interval)
Proportional error for glucuronide 19.6 (27.5) 19.7 (27.9) 19.3 (14.7–25.0)
Proportional error for sulphate 18.4 (20.3) 18.5 (20.6) 18.3 (15.1–22.0)
Proportional error for cys and mercap 24.8 (9.2) 25.0 (8.7) 24.9 (22.7–27.0)
OFV [- 2LL] -2937.3 -3085.4 -3147.2 (-3592.4 to -2759.2)
CLgluc glucuronidation clearance, CLsulp sulphation clearance, CLCYP2E1 CYP2E1-mediated clearance, CLE gluc glucuronide elimination clear-
ance, CLE sulph sulphate elimination clearance, CLE cys&mercap cysteine & mercapturate elimination clearance, KtrCYP2E1 CYP2E1 transit
compartment rate constant, Ktrgluc glucuronide transit compartment rate constant, LBW lean body weight, OFV objective function value, Q inter-
compartmental clearance of acetaminophen sulphate between the central and peripheral compartment, TBW total body weight, V volume of
distribution, -2LL -2 log likelihood(see also Fig. 1)
a The mean transit time was 158.7 min
b The mean transit time was 175.4 min
c The mean transit time was 10.5 min
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Fig. 3 Empirical Bayes estimates for morbidly obese patients
(n = 20; black circles) and non-obese patients (n = 8; grey circles)
versus lean body weight (LBW), including a glucuronidation
clearance (CLgluc), b sulphation clearance (CLsulph) and c cytochrome
P450 2E1–mediated clearance (CLCYP2E1) [base pharmacokinetic
model]
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Fig. 4 Observed versus
individual-predicted and
observed versus population-
predicted concentrations of
acetaminophen (top row),
acetaminophen glucuronide
(second row), acetaminophen
sulphate (third row) and
acetaminophen cysteine and
mercapturate (bottom row) in
the final model for morbidly
obese patients (n = 20; black
circles) and non-obese patients
(n = 8; grey circles). Ln log-
normal
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Fig. 5 Visual predictive checks
of the final model for
acetaminophen (top row),
acetaminophen glucuronide
(second row), acetaminophen
sulphate (third row) and
acetaminophen cysteine and
mercapturate [cys and mercap]
(bottom row) in morbidly obese
patients (left graphs) and non-
obese patients (right graphs).
The observed concentrations are
shown as blue circles, and the
medians (and 2.5th and 97.5th
percentiles) of the observed data
are shown as solid red lines (and
lower and upper dashed red
lines, respectively). The pink
shaded areas represent the
95 % confidence intervals for
the medians of the simulated
concentrations (n = 1000),
based on the original data set,
and the lower and upper blue
shaded areas represent the
95 % confidence intervals of the
2.5th and 97.5th percentiles,
respectively
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observed data and the model-simulated confidence inter-
vals for the medians and the 2.5th and 97.5th percentiles
(Fig. 5).
3.4 Simulations
Figure 6 shows population-predicted acetaminophen,
acetaminophen glucuronide, acetaminophen sulphate, and
acetaminophen cysteine and mercapturate concentrations
after a 2 g intravenous dose of acetaminophen adminis-
tered over 20 min in four representative patients (with
TBWs of 60.1, 106, 134 and 193 kg, and LBWs of 41.2,
51.3, 65.8 and 96.2 kg, respectively). The maximum con-
centration (Cmax) value for acetaminophen and Cmax and
tmax values for acetaminophen glucuronide were lower in
patients with greater body weight (Fig. 6a, b). For acet-
aminophen sulphate, the Cmax and tmax values were slightly
lower in heavier patients (Fig. 6c). For acetaminophen
cysteine and mercapturate, the Cmax value was higher and
the tmax value was lower in patients with greater body
weight (Fig. 6d).
3.5 24-h Liver Function Markers
Morbidly obese patients had significantly higher AST,
ALT, bilirubin and PT values at 24 h after the 2 g intra-
venous acetaminophen infusion than before acetaminophen
administration (P\ 0.05, Table 3). Two morbidly obese
patients had more than three times increased AST levels
(i.e. 102 and 140 U/L), and one morbidly obese patient had
more than three times increased ALT levels (i.e. 128 U/L).
Non-obese patients did not show significantly elevated
AST or ALT levels at 24 h in comparison with the levels
before acetaminophen administration, with significant
increases only in bilirubin and PT values (P\ 0.05,
Table 3).
4 Discussion
In view of the known induced CYP2E1 metabolism in
obese individuals, this study aimed to determine the
pharmacokinetics of acetaminophen and all of its
metabolites (glucuronide, sulphate, cysteine and mercap-
turate) in morbidly obese versus non-obese patients. The
results of this study show that the lower exposure to
acetaminophen in morbidly obese patients resulting from
an increased total clearance of acetaminophen, as has been
reported before [13], can be explained by increases in all
three metabolic pathways (i.e. glucuronidation, sulphation
and CYP2E1-mediated clearance).
This study is the first to report an increased CYP2E1-
mediated clearance of acetaminophen in morbidly obese
patients. Previously, this pathway has been investigated
only in obese rats, where clearance to the cysteine and
mercapturate metabolites was increased by 56 % after
administration of a sub-toxic dose of acetaminophen [22].
The increased CYP2E1-mediated clearance in the obese is
consistent with investigations on other CYP2E1-mediated
drugs, i.e. chlorzoxazone, enflurane and sevoflurane [15,
18, 33, 34]. NAFLD may be the underlying cause of
increased CYP2E1 expression in obese patients [24].
NAFLD refers to a large spectrum of conditions ranging
from fatty liver to non-alcoholic steatohepatitis (NASH)
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Fig. 6 Population-predicted acetaminophen concentrations (first
graph), acetaminophen glucuronide concentrations (second graph),
acetaminophen sulphate concentrations (third graph) and acetamino-
phen cysteine and mercapturate concentrations (fourth graph) over
time in one non-obese patient (with total body weight [TBW] of
60.1 kg and lean body weight [LBW] of 41.2 kg) and in three
morbidly obese patients (with TBWs of 106, 134 and 193 kg; and
with LBWs of 51.3, 65.8 and 96.2 kg, respectively) after 2 g of
intravenous acetaminophen
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and cirrhosis [11, 24]. Different studies have shown a
causal relationship between CYP2E1-mediated clearance
[18, 19] or protein expression and steatosis or NASH
measured with a needle biopsy of the liver [17–19]. In
addition, weight loss has been associated with a significant
decrease in CYP2E1-mediated clearance and CYP2E1
protein content after bariatric surgery [17, 33], with the
decrease in CYP2E1-mediated clearance protein content
being associated with a significant reduction in lipid per-
oxidation levels [17]. Another cause of the increased
expression of CYP2E1 that has been postulated is insulin
resistance, which is often observed in obese individuals
[24].
Besides increased CYP2E1-mediated clearance, our
study showed an increase in glucuronidation clearance of
acetaminophen with increasing LBW. Higher absolute
acetaminophen clearance values and 2-fold higher acet-
aminophen glucuronide urine concentrations have also
been reported in obese adolescents with NAFLD in com-
parison with non-obese adolescents without NAFLD [15,
16]. In addition, for other UGT-mediated drugs (i.e. gar-
enoxacin, oxazepam and lorazepam), increased clearance
has been demonstrated in obese subjects in comparison
with non-obese subjects [14, 15]. However, Hardwick et al.
[23] reported no alteration in UGT activity of acet-
aminophen in human liver tissue samples diagnosed with
NAFLD, but this UGT activity was reported per milligram
of protein and not per liver. In addition, no alteration in the
glucuronidation capacity of morphine was reported by
Ferslew et al. [35], since morphine pharmacokinetics did
not differ between obese patients with NASH and non-
obese healthy subjects. The differences in the findings on
morphine and acetaminophen may, in our opinion, be
explained by the fact that morphine—in contrast to acet-
aminophen—is a relatively high-extraction-ratio drug of
which the clearance is dependent on hepatic blood flow
[36]. The fact that in that study, elevated morphine glu-
curonide concentrations were found in obese NASH
patients, were (according to the authors) explained by
alterations in hepatic membrane transporters, i.e. multidrug
resistance-associated protein (MRP)-3, instead of increased
glucuronidation clearance of morphine [35]. Recently,
Canet et al. [37] reported increased acetaminophen glu-
curonide concentrations in paediatric NASH patients. In
their opinion, these results could be explained by hepatic
membrane transporter dysregulation of MRP2 and MRP3.
Their conclusions were, however, based on three NASH
patients and on glucuronide concentrations only, without
modelling of the data in a population model. Given the
results of the current study, we think it is justified to con-
clude that glucuronidation capacity is increased in mor-
bidly obese patients.
In this report, we show an increase in sulphation of
acetaminophen with weight. Previously, changes in the
sulphate conjugation pathway were examined only in obese
rodent models, showing contradictory results [20–22]. In
human NAFLD liver microsomes, an increase in sulfo-
transferase activity was reported in steatosis liver samples,
but there was decreased activity in NASH liver samples
(per milligram of protein) [23]. Moreover, in paediatric
Table 3 Liver function markers before (T = 0) and 24 h after (T = 24) the 2 g intravenous acetaminophen dose and subsequent standard-of-
care doses of acetaminophen in morbidly obese and non-obese patients
Liver function markers Morbidly obese patients, n = 20 Non-obese patients, n = 8
T = 0, n = 20 T = 24, n = 18a P value T = 0, n = 8 T = 24, n = 8b P value
AST [U/L];
RR: #\ 35 U/L, $\ 31 U/L
26.0 (14.0–40.0) 34.5 (20.0–140.0) 0.017 22.0 (18.0–28.0) 22.5 (17.0–52.0) [0.05
ALT [U/L];
RR: #\ 45 U/L, $\ 34 U/L
30.5 (12.0–58.0) 38.5 (14.0–128.0) 0.022 19.5 (7.0–33.0) 18.0 (7.0–28.0) [0.05
c-GT [U/L];
RR: #\ 55 U/L, $\ 38 U/L
29.5 (13.0–99.0) 29.0 (14.0–82.0) [0.05 12.5 (8.0–27.0) 11.0 (4.0–28.0) 0.048
Bilirubin [lmol/L];
RR: 1–17 lmol/L
6.0 (3.0–17.0) 7.0 (4.0–20.0) 0.014 8.0 (4.0–18.0) 12.0 (6.0–29.0) 0.012
PT [s];
RR: 12.0–15.5 s
12.8 (12.3–13.9), n = 15 13.3 (13.0–13.7), n = 13 0.004 12.9 (12.4–13.4) 14.1 (13.0–16.2) 0.012
Values are expressed as median (range)
# male, $ female, c-GT c-glutamyltranspeptidase, ALT alanine aminotransferase, AST aspartate aminotransferase, PT prothrombin time,
RR reference range
a The total administered dose over 24 h was 2 g of intravenous acetaminophen plus median standard-of-care doses of acetaminophen 3 g (0–3 g)
b The total administered dose over 24 h was 2 g of intravenous acetaminophen plus median standard-of-care doses of acetaminophen 2 g (0–4 g)
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NASH patients, a non-significant decrease in acet-
aminophen sulphate concentrations was reported [37]. In
our study, we found a correlation between the patients’
triglyceride levels and CLsulph (DOFV -17), but since
weight and triglycerides were correlated, LBW was
included in the model. Because of these results, we think
that our finding of an increase in sulphation with weight
could be caused by steatosis of the liver in morbidly obese
patients.
The dose simulations based on the final model in Fig. 6
illustrate the clinical relevance of the findings of this study.
The acetaminophen Cmax values were substantially lower
in patients with greater body weight, because of the greater
volume of distribution of acetaminophen with increasing
LBW (Fig. 6a). The acetaminophen half-life (t) was equal
for morbidly obese and non-obese patients (Fig. 6a) and
can be explained by an increase in both the volume of
distribution and clearance of acetaminophen. For acet-
aminophen glucuronide, tmax decreased with increasing
weight (Fig. 6b), because of greater glucuronidation
clearance. The Cmax of acetaminophen glucuronide was
lower with increasing weight (Fig. 6b) and could be
explained by the greater glucuronide elimination clearance
with LBW and by the increases in volume of distribution of
acetaminophen and glucuronide with increasing weight.
Despite greater sulphation clearance, the concentration–
time profile values of acetaminophen sulphate were slightly
lower in morbidly obese patients than in non-obese patients
(Fig. 6c), which could be explained by the greater Vac-
etaminophen. For acetaminophen cysteine and mercapturate,
the tmax was shorter in morbidly obese patients, because of
the higher CYP2E1 transit compartment rate constant of
acetaminophen, leading to a decrease in the mean transit
time. Despite the increase in CYP2E1-mediated clearance,
the Cmax values were only slightly higher in morbidly
obese patients than in non-obese patients, because of the
greater volume of distribution of acetaminophen with
LBW.
Although the absolute cysteine and mercapturate AUC
values were not substantially higher in morbidly obese
patients (Fig. 6), we emphasize that one should be reluctant
to give a higher acetaminophen dose to obese individuals,
as it is not known whether earlier and greater formation of
CYP2E1-mediated metabolites may contribute to acet-
aminophen hepatotoxicity. Moreover, the AUC0–8h ratio of
the cysteine metabolite was significantly increased in
morbidly obese patients (Fig. 2). Increasing the standard
dose from 1 to 2 g in morbidly obese patients is therefore
not recommended, despite our finding that acetaminophen
concentrations are lower in morbidly obese patients than in
non-obese patients. This advice is further substantiated by
the significantly increased AST, ALT, bilirubin and PT
values at 24 h after the initial 2 g administration (with total
median doses over 24 h of 4 g [range 2–6 g] in non-obese
patients and 5 g [2–5 g] in morbidly obese patients,
P[ 0.05) in comparison with the levels before acet-
aminophen administration, although these values were still
close to the reference ranges (Table 3). Two morbidly
obese patients had[3 times increased levels of AST, and
one patient had a [3 times increased level of ALT in
comparison with the reference values (shown in Table 3).
While the exact values of these increases—which may
potentially relate to the bariatric surgical procedure itself—
are unknown, the difference in comparison with non-obese
patients is clear (Table 3).
There were some limitations of this study. First, the
surgery time in the non-obese patients was significantly
longer in comparison with the obese patients, which may
potentially have influenced the pharmacokinetics of acet-
aminophen. Second, the study can be considered as a small
study (n = 20 ? 8), although for pharmacokinetic studies,
a smaller number of patients is typically accepted. Third,
whether the patients suffered from NAFLD could not be
determined in this study, since there was no possibility to
take a liver biopsy from these patients. To gain an
impression as to whether the morbidly obese patients were
metabolically different from the non-obese patients, sam-
ples for insulin resistance, lipid levels and CRP levels
(Table 1) were collected.
5 Conclusion
Obesity leads to lower acetaminophen concentrations, with
earlier and higher peak concentrations of the cysteine and
mercapturate metabolites. While a higher dose may be
anticipated to achieve adequate acetaminophen concentra-
tions, the increased CYP2E1-mediated pathway may pre-
clude this dose adjustment.
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